Figure 1
From: The impact of COVID-19 on microRNA and CD marker expression in AML patients
Clinical evaluation of AML patients and characterisation of PBMCs with signature marker detection. (A) Complete Blood Count (CBC) Parameters in AML patients and healthy donors. (B) The expression of a cluster of differentiation CD markers in AML patients. (C) Fluorescence in Situ Hybridization (FISH) probe and genetic abnormalities ratios in AML patients. (D) Analysis of FLT3 mutation frequency in AML patients and healthy controls. The data were presented as means of parameter values. CBC Complete blood count, WBC white blood cell, LYM% lymphocyte percentage, LYM lymphocyte count, RBC red blood cell, HCT haematocrit, MCH mean cell haemoglobin, PLT platelet count, *Statistically significant at 0.05 level.
